Valvular heart disease
Conditions
Interventions
Group E :Comprehensive Lung Protection Interventions
Group A :No intervention measures
Group B :Oral care and pulmonary prehabilitation education.
Group C :Intraoperative lung-protective ventilation (LPV)
Group D:Continuous intravenous infusion of sivelestat sodium at 4.8 mg·kg?1
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1: Age >=18 years; 2: Scheduled for median sternotomy valve surgery under CPB; 3: Cardiac function (NYHA class) II–III; 4: Written informed consent obtained from patients or legal representatives.
Exclusion criteria
Exclusion criteria: 1: Severe non-cardiac pulmonary disease; 2: Acute respiratory infection within 1 month preoperatively, with symptom resolution 35 kg/m² or obstructive sleep apnea syndrome; 7: Inability to communicate (coma, severe dementia, or language barrier); 8: Re-do open-heart surgery under CPB; 9: Participation in other interventional trials or experimental drug use within 3 months; 10: Poor compliance or inability to complete the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PPC incidence within 7 days postoperatively ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative ventilator use time;Length of hospital stay;Postoperative extrapulmonary complications;28-day postoperative mortality rate;Plasma levels of TNF-a, IL-6, IL-8, and IL-10 at 24 and 48 hours after surgery;Plasma levels of sRAGE, CC16, and Ang-2 at 24 and 48 hours after surgery; | — |
Countries
China
Contacts
Public ContactZhou Lifang
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed